Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer
Open Access
- 30 June 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 113 (2), 199-203
- https://doi.org/10.1038/bjc.2015.215
Abstract
Background: Selumetinib (AZD6244, ARRY-142886)+docetaxel increases median overall survival (OS) and significantly improves progression-free survival (PFS) and objective response rate (ORR) compared with docetaxel alone in patients with KRAS mutant, stage IIIB/IV non-small-cell lung cancer (NSCLC; NCT00890825). Methods: Retrospective analysis of OS, PFS, ORR and change in tumour size at week 6 for different sub-populations of KRAS codon mutations. Results: In patients receiving selumetinib+docetaxel and harbouring KRAS G12C or G12V mutations there were trends towards greater improvement in OS, PFS and ORR compared with other KRAS mutations. Conclusion: Different KRAS mutations in NSCLC may influence selumetinib/docetaxel sensitivity.Keywords
This publication has 13 references indexed in Scilit:
- Panel Based MALDI-TOF Tumour Profiling Is a Sensitive Method for Detecting Mutations in Clinical Non Small Cell Lung Cancer TumourPLOS ONE, 2014
- Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)Annals of Oncology, 2013
- KRAS Mutations as Prognostic and Predictive Markers in Non–Small Cell Lung CancerJournal of Thoracic Oncology, 2013
- Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 studyThe Lancet Oncology, 2013
- Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomasCancer, 2012
- A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic responseNature, 2012
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical OutcomeJNCI Journal of the National Cancer Institute, 2012
- The BATTLE Trial: Personalizing Therapy for Lung CancerCancer Discovery, 2011
- Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancerAnnals of Oncology, 2011
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000